Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Swiss National Bank

Swiss National Bank raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 7.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 250,700 shares of the company’s stock after purchasing an additional 17,900 shares during the quarter. Swiss National Bank’s holdings in Denali Therapeutics were worth $7,303,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bayesian Capital Management LP acquired a new position in Denali Therapeutics during the first quarter worth approximately $447,000. Candriam S.C.A. increased its position in shares of Denali Therapeutics by 62.2% in the second quarter. Candriam S.C.A. now owns 726,499 shares of the company’s stock worth $16,869,000 after acquiring an additional 278,621 shares in the last quarter. Integral Health Asset Management LLC acquired a new stake in shares of Denali Therapeutics in the second quarter worth $7,546,000. Vanguard Group Inc. increased its position in shares of Denali Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,968,293 shares of the company’s stock worth $225,069,000 after acquiring an additional 133,810 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Denali Therapeutics by 13.3% in the second quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock worth $4,525,000 after acquiring an additional 22,900 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on DNLI shares. JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Wedbush dropped their price objective on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Citigroup upped their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Jefferies Financial Group upped their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Bank of America upped their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $38.90.

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI opened at $24.50 on Tuesday. The stock has a market capitalization of $3.53 billion, a price-to-earnings ratio of -8.88 and a beta of 1.40. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.33. The company’s fifty day moving average is $27.88 and its two-hundred day moving average is $24.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business earned ($0.72) EPS. Sell-side analysts expect that Denali Therapeutics Inc. will post -2.69 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now owns 29,096 shares of the company’s stock, valued at $844,656.88. This trade represents a 50.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now directly owns 235,807 shares in the company, valued at approximately $6,529,495.83. This trade represents a 14.50 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 86,578 shares of company stock valued at $2,474,440. Company insiders own 7.90% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.